



31 January 2019

ASX Announcement

Race Receives \$228k R&D Tax Incentive Refund

31 January 2019: Race Oncology Limited ("RAC") is pleased to announce that the Company has received a \$228,501 R&D Tax Incentive refund for the 2017/2018 financial year.

The R&D Tax Incentive is an important Australian Government Program that refunds up to 43.5% of eligible expenditure on research and development.

About Race Oncology (RAC. ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned after a series of pharmaceutical mergers. Bisantrene has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US patents and has been awarded US Orphan Drug designation and a Rare Paediatric Disease designation.

Media contact:

Heidi Cuthbert, +61 411 272 366

E: heidi.cuthbert@multiplier.com.au